Hodgkins Disease Clinical Trial
— Breast SparingOfficial title:
Breast-Sparing Proton Therapy for Hodgkin's Disease in Young Females Demonstrated By Positron Emission Tomograpy (PET) Scanning: A Pilot Study
Verified date | February 2015 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to drastically reduce unnecessary breast dose in young females with Hodgkin's Disease who require radiation therapy.
Status | Terminated |
Enrollment | 3 |
Est. completion date | February 2015 |
Est. primary completion date | February 2015 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 10 Years to 30 Years |
Eligibility |
Inclusion Criteria: - Female sex - Age >/= 10 years old and < 30 years old - Pathologically confirmed classical Hodgkin's Lymphoma - At least one site of disease located above the diaphragm - Signed study-specific consent prior to initiation of therapy - Women of child-bearing potential must have a negative pregnancy blood test within 7 days of starting protocol therapy. Exclusion Criteria: - Previous radiation therapy to any part of the body. - Parenchymal lung involvement at initial presentation or any patient that may need whole lung irradiation as per institutional guidelines. - Lymphocyte predominant histology not eligible. - Significant infection or other coexistent medical condition that would preclude protocol therapy such as: - History of HIV/AIDS - History of collagen Vascular Disease - Symptomatic congestive heart failure - Unstable angina pectoris or myocardial infarction within 6 months - Uncontrolled hypertension (systolic blood pressure > 160 mm Hg or diastolic blood pressure > 100 mm Hg on 2 consecutive measurements separated by 1 week). - History of uncontrolled diabetes - Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Indiana University Health Proton Therapy Center | Bloomington | Indiana |
Lead Sponsor | Collaborator |
---|---|
Indiana University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparative DVH data for delivered proton plan and accompanying photon plan for target volume and normal tissues. | Dose-volume histogram data from both the delivered proton plan and the accompanying photon plan for target volumes and normal tissues, including: • Breast, heart, lung, thyroid, parotid glands , esophagus, spinal cord, *liver, *kidneys, |
12 months | Yes |
Secondary | Treatment toxicity and disease control of proton therapy for the treatment of pediatric Hodgkin's Lymphoma. | Acute toxicity as per CTCAE v4.0 Local, regional, and distal control of the disease at 3 years |
3 - 60 Months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00764829 -
Blood Samples to Evaluate Biomarkers of Donor Chimerism
|
N/A | |
Terminated |
NCT01500161 -
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
|
Phase 2 | |
Completed |
NCT00901225 -
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT02639559 -
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00697684 -
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT00802113 -
Autologous and Allogeneic Transplant for Relapsed Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT01951885 -
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
|
Phase 3 | |
Completed |
NCT00754286 -
A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer
|
N/A | |
Completed |
NCT00364676 -
Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease
|
Phase 1 | |
Completed |
NCT00571662 -
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT00713882 -
Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors
|
N/A |